Release details

2016-01-04 13:00 CET
  • Print
  • Share Share

Nexstim Plc publishes a Company Description



Helsinki, 4 January 2016 at 2:00 p.m.

On 17 December 2015 Nexstim Plc ("Nexstim" or the "Company") announced the results of a directed share issue on the basis of a book-building process targeted towards certain institutional investors in a private placement (the "Private Placement"). In the Private Placement, the Company issued 880,000 new shares (the "Issue Shares"), representing approximately 11.9 per cent of all of the shares in the Company prior to the Private Placement and approximately 11.0 percent of all the shares in the Company after the registration of the Issue Shares. The Issue Shares were registered with the Finnish Trade Register and delivered through Euroclear Finland and Euroclear Sweden on 23 December 2015.

Nasdaq Helsinki Ltd has today approved the English-language Company Description prepared by the Company for the purposes of listing the Issue Shares on Nasdaq First North Finland and Nasdaq First North Sweden, and the Company hereby publishes the Company Description. The Company Description is available in the English language from 6:00 p.m. onwards on 4 January 2016 on the Company's website and at the Company's head office at Elimäenkatu 9 B, 00510 Helsinki, Finland.

The Company expects that, following publication of the Company Description, the Issue Shares will be listed on Nasdaq First North Finland and Nasdaq First North Sweden, respectively, on 7 January 2016.

ABG Sundal Collier AB acted as arranger in connection with the Private Placement. Krogerus Attorneys Ltd is legal advisor to the Company. The Company's Certified Adviser under the First North rules is UB Securities Ltd.

For further information please contact:

Janne Huhtala, Chief Executive Officer

+358 40 8615046
UB Securities Ltd (Certified Adviser)

+358 9 2538 0246

About Nexstim Plc

Nexstim is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke therapy called Navigated Brain Therapy (NBT®). In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the US aiming to demonstrate the effectiveness of NBT® and gain FDA clearance for commercialisation in post-acute stroke therapy in the US. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. In H2 2015, the Company received a recommendation from the Data Safety Monitoring Board (DSMB) to continue the Phase III stroke therapy NICHE trial without any modifications. The first interim analysis on the NICHE (Navigated Inhibitory rTMS to Contralesional Hemisphere) trial using NBT® was performed after 81 patients reached their primary safety outcome assessment, on track, at six months post-treatment. For more information please visit


The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

The information contained herein is not for publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan or South Africa. These written materials do not constitute an offer of securities for sale in the United States, nor may the securities be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. There is no intention to register any portion of the offering in the United States or to conduct a public offering of securities in the United States.

Members of the public are not eligible to take part in the offering. This communication is directed (A) in the European Economic Area, only at persons who are qualified investors as defined in article 2(1)(e) of EU directive 2003/71/EC, as amended, and as implemented in legislation in each of the relevant member states and (B) in the United Kingdom only at qualified investors who are: (i) investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) order 2005 (the "Order"), or (ii) persons falling within article 49(2) ("high net worth companies, unincorporated associations, etc") of the Order (all such persons together being referred to as "relevant persons"). Any investment activity to which this communication relates will only be available to and will only be engaged with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

This announcement contains forward looking statements. These forward looking statements include statements that are not historical facts and statements concerning inter alia Nexstim's future revenues, financial position, financial standing, prospects, growth, strategies and its plans, beliefs and current expectations in relation to its field of business. By their very nature, forward looking statements involve inherent risks and uncertainties, since they relate to events or result from circumstances that may or may not occur in the future, and therefore they only describe the circumstances prevailing when the statement is given. Nexstim cautions that forward looking statements or historical facts do not guarantee future performance and that its true revenues, financial position and financial standing and the development of the industry may significantly differ from the forward looking statements presented in this release. The Company does not intend and does not assume any obligation to update any forward looking statement contained herein.